TrialAssure Wins ISO 27001:2022 Certification for AI Drug Development Tools

TrialAssure said Aug. 20, 2026, that it earned ISO/IEC 27001:2022 certification for its information security management system as pharma and biotech companies increase use of AI in regulated workflows. The company says the certification is meant to strengthen trust in its clinical trial transparency and life sciences software portfolio.

Why it matters: - TrialAssure’s certification is meant to reassure drug developers that AI tools used for regulated work can meet globally recognized security standards. - The milestone comes as pharmaceutical and biotechnology companies expand AI use in medical writing, regulatory operations and clinical trial transparency. - Strong information security has become a core requirement for software handling sensitive clinical and regulatory data.

What happened: - TrialAssure announced it achieved ISO/IEC 27001:2022 certification for its Information Security Management System on Aug. 20, 2026. - The certification applies to TrialAssure’s secure technology platform and its growing portfolio of AI life science software solutions. - The company is based in Canton, Michigan.

The details: - ISO/IEC 27001:2022 is an international standard for information security management systems. - The standard provides a framework for managing security risks, protecting sensitive data and improving security practices over time. - TrialAssure said the certification means its information security program was independently audited and verified against global standards. - The certification supports LINK AI for AI-assisted medical writing, ANONYMIZE for document and data anonymization, REGISTRY for clinical trial disclosure and TrialAssure’s broader software suite. - TrialAssure said the portfolio helps life sciences organizations simplify compliance, improve operational efficiency and support global transparency requirements. - More information is available in the company's announcement.

Between the lines: - The certification is a market signal as much as a security milestone, especially for buyers weighing AI performance against compliance and data protection risks. - TrialAssure is positioning security as part of the value proposition for AI adoption in heavily regulated drug development workflows. - The move also helps the company differentiate its platform in a crowded life sciences software market where trust can determine adoption.

What's next: - TrialAssure is likely to use the certification in sales and customer assurance efforts as demand grows for AI tools that can operate in regulated environments. - The company’s broader push centers on secure AI and clinical technology solutions for transparency, disclosure and compliance use cases.

The bottom line: - TrialAssure is betting that security certification will make its AI tools more credible to pharmaceutical and biotech customers deciding how fast to adopt AI in drug development.